Dianosic plans to raise EUR 10m in Series A; to seek exit sale around 2026
Discover our other articles
Dianosic launches a WiSEED backed convertible bonds transaction to accelerate innovation in the treatment of chronic allergic rhinitis. This initiative aims to support the…
Oct 13, 2024
Dianosic shortlisted for the “Trophées des Entreprises Alsace 2024” award
Awards
We are delighted to announce that Dianosic is one of the nominees for the 2024 edition of the “Trophées des entreprises d’Alsace”. This selection…
Dianosic joins France Deeptech! 🇫🇷 🚀 We are delighted to inform you of Dianosic’s official integration into the deeptech ecosystem! A dynamic network that…
